Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.75 |
| ▸ | MAOB | P27338 | 10/20 | 0.70 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17042739 | 0.98 | TAAR1 (0.72) | TAAR1MAOBMAOA | |
| SCHEMBL6311979 | 0.89 | TAAR1 (0.67) | TAAR1MAOBST14 | |
| SCHEMBL232327 | 0.87 | TAAR1 (1.00) | TAAR1MAOB | |
| SCHEMBL17085328 | 0.86 | TAAR1 (0.55) | TAAR1MAOBST14 | |
| Hydrochloric Acid SCHEMBL17042613 | 0.85 | MAOB (0.56) | TAAR1MAOBST14 | |
| Iodide SCHEMBL29127481 | 0.84 | TAAR1 (0.95) | TAAR1MAOB | |
| Hydrochloric Acid SCHEMBL1924679 | 0.84 | TAAR1 (0.95) | TAAR1MAOB | |
| Bromide SCHEMBL28684127 | 0.84 | TAAR1 (0.95) | TAAR1MAOB | |
| Hydrochloric Acid SCHEMBL10897947 | 0.84 | TAAR1 (0.95) | TAAR1MAOB | |
| SCHEMBL1049649 | 0.83 | ALDH1A1 (0.64) | TAAR1MAOBMAOAST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2913325-B1 | SUBSTITUTED PYRIMIDINE COMPOUND AND USES THEREOF | SHENYANG SINOCHEM AGROCHEMICALS R & D CO LTD (CN) | 2021-04-21 | — | — | EP | disclosed |
| EP-3760617-A1 | SUBSTITUTED PYRIMIDINE COMPOUND AND USES THEREOF | Shenyang Sinochem Agrochemicals R&D Co., Ltd. (CN) | 2021-01-06 | — | — | EP | disclosed |
| US-9770026-B2 | Substituted pyrimidine compound and uses thereof | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2017-09-26 | — | — | US | disclosed |
| EP-2649053-B1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LTD (GB) | 2015-11-04 | — | — | EP | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-20150257385-A1 | Substituted Pyrimidine Compound and Uses Thereof | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2015-09-17 | — | — | US | disclosed |
| EP-2913325-A1 | SUBSTITUTED PYRIMIDINE COMPOUND AND USES THEREOF | Sinochem Corporation (CN) | 2015-09-02 | — | — | EP | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| WO-2012076435-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2 | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076435-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2 | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142717-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-20120142717-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-20120142717-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| EP-2096107-A1 | Derivatives of squaric acid with anti-proliferative activity | GPC Biotech AG (DE) | 2009-09-02 | — | — | EP | disclosed |
| EP-1674457-B1 | Derivatives of squaric acid with anti-proliferative activity | GPC BIOTECH AG (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-20080200523-A1 | Derivatives of squaric acid with anti-proliferative activity | Valo Health, LLC | 2008-08-21 | — | — | US | disclosed |
| EP-1674457-A1 | Derivatives of squaric acid with anti-proliferative activity | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| US-20050054582-A1 | Para-amino benzoic acids as integrin antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150257385-A1 | Substituted Pyrimidine Compound and Uses Thereof | TYR, GART, LRRK2 | TAAR1 437/4885MAOB 87/4885MAOA 483/4885 |
| US-20120142717-A1 | COMPOUNDS | LIPG, PLA2G1B, ENPP2 | TAAR1 3528/4885MAOB 991/4885MAOA 759/4885 |
| US-20050054582-A1 | Para-amino benzoic acids as integrin antagonists | ITGB7, ICAM1, ITGB1 | TAAR1 1301/4885MAOB 3301/4885MAOA 3367/4885 |
| US-20080200523-A1 | Derivatives of squaric acid with anti-proliferative activity | SQLE, FDFT1, DLD | TAAR1 4581/4885MAOB 4297/4885MAOA 4494/4885 |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | TAAR1 1985/4885MAOB 861/4885MAOA 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.